Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Temozolomide-associated hypermutation in gliomas.

Neuro-oncology - 3 Sept 2018

Choi Serah, Yu Yao, Grimmer Matthew R, Wahl Michael, Chang Susan M, Costello Joseph F

Abstract excerpt

Low-grade gliomas cause considerable morbidity and most will recur after initial therapy. At recurrence, low-grade gliomas can undergo transformation to high-grade gliomas (grade III or grade IV), which are associated with worse prognosis. Temozolomide (TMZ) provides survival benefit in patients with glioblastomas, but its value in patients with low-grade gliomas is less clear. A subset of TMZ-treated, isocitrate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Brain Neoplasms
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair Enzymes

Share to Drug Resistance, Neoplasm

Share to Glioma

Share to Neoplasm Recurrence, Local

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 29452419
DOI: 10.1093/neuonc/noy016
PMCID: PMC6120358

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Temozolomide-associated hypermutation in gliomas.PMID 29452419Read ↗

Mechanisms and therapeutic implications of hypermutation in gliomas.Semantic proximity Read ↗

The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management.Semantic proximity Read ↗

Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.Semantic proximity Read ↗

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive reviewSemantic proximity Read ↗

Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutationsSemantic proximity Read ↗

Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas.Semantic proximity Read ↗

Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution.Semantic proximity Read ↗

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrenceSemantic proximity Read ↗

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferaseSemantic proximity Read ↗

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.Semantic proximity Read ↗

Evolving Molecular Genetics of Glioblastoma.Semantic proximity Read ↗

Low-Grade Gliomas: A New Mutation, New Targeted Therapy, and Many Questions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.